Gen-Probe, Incorporated

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Gen-Probe, Incorporated sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 11 completed later-stage tilt top decile by trial count

Gen-Probe, Incorporated: 12 sponsored US clinical trials, none currently recruiting.

Gen-Probe, Incorporated sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Trichomonas Vaginalis, with 1 trials.

Top-decile sponsor footprint

Gen-Probe, Incorporated ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 69/100

11 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

12 total, page 1 of 1

COMPLETED

Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay

NCT02026752
COMPLETED

Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican and US Blood Donors - CTS

NCT01702272
TERMINATED

Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays

NCT01728103
COMPLETED

Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the PANTHER® System

NCT01694875
COMPLETED

Female Urine, Vaginal & Endocervical Swab & Cervical Specimen Collections for APTIMA Trichomonas Vaginalis Assay Testing

NCT01427023
COMPLETED

Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican Blood Donors - American Red Cross

NCT01656174
COMPLETED

Clinical Evaluation of the APTIMA® HPV Assay Using the PANTHER™ System

NCT01446198
COMPLETED

Prospective Collection of Female and Male Specimens for PANTHER® System Testing

NCT01638637
COMPLETED

APTIMA HPV 16 18/45 Genotype Assay on the TIGRIS DTS System in Women With ASC-US or Negative Pap Test Results

NCT01384370
COMPLETED

Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHER™ System

NCT01733069
COMPLETED NA

Clinical Evaluation of the PROGENSA(Registered Trademark) Prostate Cancer Gene 3 (PCA3) Assay in Men With a Previous Negative Biopsy Result

NCT01024959
COMPLETED Phase 3

Clinical Evaluation of the APTIMA® HPV Assay Using the TIGRIS® System

NCT00973362

Phase Distribution

PhaseTrial count
Phase 3 1

Therapeutic Areas

Trichomonas Vaginalis 1
Dengue 1
Human Papillomavirus Infection 1

How the Gen-Probe, Incorporated archive is shaped

12 indexed studies, none listed as recruiting (0% open); 11 completed (92%).

Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Trichomonas Vaginalis (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Gen-Probe, Incorporated: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Gen-Probe, Incorporated sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share Gen-Probe, IncorporatedAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.Angiodynamics10xBio22nd Century Group23andMe3-C Institute for Social Development
Gen-Probe, Incorporated sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Gen-Probe, Incorporated sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Gen-Probe, Incorporated page

12 registered trials is a research-attention snapshot, not an endorsement of Gen-Probe, Incorporated or any single study.

  • None of Gen-Probe, Incorporated's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Trichomonas Vaginalis is the condition Gen-Probe, Incorporated studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Trichomonas Vaginalis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Gen-Probe, Incorporated pipeline card: 12 registered trials from official public datasets.Report a data error.